Visiongain, a independent media company, issued the following news:. Visiongain has launched a new pharma report Top Pre-Filled Injection Device Manufacturers 2018-2028: Profiles, R&D and Revenue Forecasting for Leading Syringe, Injector and Component Producers and Contract Filling Services. Pre-filled syringes provide users with a number of advant
Biologic injectors are the injecting devices used to deliver drugs and other substances for biological purposes. Biological products such as drugs, growth hormones, antibodies and other complex biological molecules are administered into the body of an organism through biologic injectors. Biologic injectors are basically used for the treatment of...
Valley Cottage, NY 11/13/2018 Increasing demand for aseptic packaging in the pharmaceutical industry is projected to be a critical factor driving the sales of blow-fill-seal equipment required for packaging forms including vials, bottles, prefilled syringes, and ampoules. Moreover, unique ability of blow-fill-seal equipment to pack formula
The tenth patient of twenty has now been recruited for the clinical study of the iron tablets Inofer, which Drugsson AB has the rights to in Sweden, Norway, Denmark and Finland. The clinical trial of Inofer was approved as previously reported, by the Swedish Medical Products Agency and the Ethical vetting board on 20 June, commencing on October 4 w
CURE Pharmaceutical, an innovative drug delivery and development company, today announced it has tapped Alex Katz to be the company s Chief Financial Officer. Our company is approaching 2019 amidst exponential growth and a clear vision to be a leader in drug delivery innovation, said Robert Davidson, CEO and Chairman of the Board of CURE
MRI guided drug delivery or magnetic resonance guided drug delivery is a part of an advanced drug delivery system that helps transport a therapeutic agent from the site of administration to the targeted area. The MRI guided drug delivery technique not only helps reduce non- target distribution of the drug but also increases drug concentration in th
Albany, NY 11/14/2018 Nasal drug delivery technology is the administration of drug through the nasal route. Nasal route of administration provides direct access to the systemic circulation. The nasal cavity is an easily accessible route which is generally well tolerated.
According to the new market research report "Nasal Drug Delivery Technology Marketby Dosage Form (Nasal Drops, Sprays, Powder, Gel), System (Multidose, Unit Dose, BI-Dose), Therapeutic Applications (Rhinitis, Congestion, Vaccinations),...
Company: KING FAHAD HOSPITAL JEDDAH. Address: Medical Services Armed Forces- King Fahd Hospital Jeddah- Direct Purchase P. O. Box 9862, Jeddah, 21159 TEL: 2328888 FAX:+ 9 663- 8936. Description: Tenders are invited for Nicotine 7 mg/ 24 hr Transdermal Patch Tender Type: Invitations/ Direct Purchase Purpose of Tender: Providing medicines to the phar
Nu-Med Plus, Inc., a medical device leader developing new nitric oxide delivery technology, announces a patent application on the new device which is designed to pretreat stored blood products with nitric oxide prior to patient transfusions. A blood transfusion is one of the most common medical procedures in the world and we believe this new N
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully randomized more than 50% of the expected 285 patients for its 90- day dose-ranging Pivotal Phase 2 b clinical study of its oral insulin capsule, ORMD-0801. The double-blind, randomiz
Stallergenes Greer Announces U.S. FDA Approval of Pediatric Indication Extension for Oralair Sublingual Immunotherapy Tablet for the Treatment of Grass Pollen Allergy. Stallergenes Greer, a biopharmaceutical company specializing in treatments for respiratory allergies, today announced that it has received approval from the U.S. Food and Drug...
Stallergenes Greer, a biopharmaceutical company specializing in treatments for respiratory allergies, today announced that it has received approval from the U.S. Food and Drug Administration for the extension of the indication for Oralair , an allergy immunotherapy sublingual tablet, to treat patients ages five to nine with grass pollen-induced..
Pune, India 11/14/2018 This report presents a 360- degree overview of the competitive scenario of the Global Injectable Drug Delivery System market. The report further projects the size and valuation of the global market in the coming forecast period. Becton, Dickinson and Company, Baxter International, Pfizer, Gerresheimer AG, Schott AG, Eli
Certara , the global leader in model-informed drug development, regulatory science, real-world evidence and market access, today announced that it has been awarded two new dermal virtual bioequivalence grants by the US Food and Drug Administration. We are delighted to receive additional US FDA support for the continuing development of our derm
Mumbai- Cipla Limited today announced that it has received final approval for its Abbreviated New Drug Application for Valganciclovir Tablets 450 mg from the United States Food and Drug Administration. Cipla's Valganciclovir Tablets 450 mg is AB-rated generic therapeutic equivalent version of Roche's Valcyte. Established in 1935, Cipla is a global.
The common shares of Ovation Science Inc., have been approved for listing on the CSE.. Ovation Science Inc. is engaged in the business of sublicensing rights to use Invisicare a patented drug delivery technology used in topical and transdermal skin products containing hemp seed oil and cannabis products. . Les actions ordi
Valley Cottage, NY 11/12/2018 Drug delivery system is the process of administering therapeutic substance through common route of administration to achieve a therapeutic effect in humans or animals. Recently, AstraZeneca signed a licensing agreement with Starpharma for the use of its DEP drug delivery technology aiming to enhancing the dosing
In continuation of the previously published poster presentation at ESMO in Munich, 19-23 October 2018, Ascelia Pharma has announced the encouraging Phase I results in a new publication titled Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokin
Nov. 12 Challenging the popular but pricey EpiPen, San Diego's Adamis Pharmaceuticals is readying its own emergency allergy medication for sale. Called Symjepi, the product is a pre-filled syringe of epinephrine, used to counteract life-threatening allergic reactions. The launch is being handled by marketing partner Sandoz, a subsidiary of Swiss.
Eyenovia, Inc., a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-dosed medications topically to the eye, today announced that the U.S. Food and Drug Administration has accepted the Company s Investigational New Drug application to initiate Phase III trial
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new clinical data for FATE- NK100, an investigational, first-in-class, allogeneic donor-derived natural killer cell cancer immunotherapy, and provided a regulatory update.
Ferring Pharmaceuticals has announced the US launch of NOCDURNA, a sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken more than two times per night to void. State University of New York Downstate Medical Center urology professor and chairman Jeffrey Weiss said: The effects of nocturia are often.
EVENT: Health and Human Services Department; Food and Drug Administration holds a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss new drug application 209774, for an immediate-release oral tablet formulation of oxycodone. The drug is intended to res
InfuSystem Holdings, Inc., a leading national provider of infusion pumps and related services for the healthcare industry in the United States and Canada, today reported financial results for the third quarter ended September 30, 2018. Absent the implementation of ASC 606, net revenues for the three and nine months ended September 30, 2018 would